Deciphera Pharmaceuticals, a clinical-stage biotech developing kinase inhibitors for solid tumors, announced terms for its IPO on Monday.
The Waltham, MA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, Deciphera Pharmaceuticals would command a fully diluted market value of $491 million.
Deciphera Pharmaceuticals was founded in 2003 and plans to list on the Nasdaq under the symbol DCPH. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of September 25, 2017.
